PDF(Pubmed)
Abstract：
The Sodium-glucose co-transporter 2 (SGLT2) inhibitor is an anti-glycemic agent that frequently used in type 2 diabetes mellitus (T2DM) with antioxidant effects. Endometrial cancer (EC) is a common gynecological malignancy that correlates with oxidative stress. The aim in the present study is to survey the potential association between the SGLT2 inhibitor administration and the incidence of EC by the application of the National Health Insurance Research Database (NHIRD) of Taiwan. A retrospective cohort study was directed and the T2DM participants were divided into the SGLT2 inhibitors users and non-SGLT2 inhibitors users. After matching, a total of 163,668 and 327,336 participants were included into the SGLT2 inhibitors and control groups, respectively. The primary outcome is regarded as the development of EC according to the diagnostic, image, and procedure codes. Cox proportional hazard regression was employed to generate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of EC between the two groups. There were 422 and 876 EC events observed in the SGLT2 inhibitors and control groups, respectively. The SGLT2 inhibitors group demonstrated a significantly lower incidence of EC formation compared to the control groups (aHR: 0.87, 95% CI: 0.76-0.99). In the subgroup analysis, the correlation between SGLT2 inhibitor administration and lower rate of EC existed in the T2DM individuals with aged under 60. Moreover, the association between SGLT2 inhibitor administration and lower EC incidence only presented in the T2DM population with SGLT2 inhibitor administration under one year (aHR: 0.58, 95% CI: 0.45-0.73). In conclusion, the administration of SGLT2 inhibitors correlates to lower incidence of EC in T2DM population.
摘要：
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一种常用于2型糖尿病（T2DM）的抗血糖药，具有抗氧化作用。子宫内膜癌（EC）是一种常见的妇科恶性肿瘤，与氧化应激相关。本研究的目的是通过应用台湾国家健康保险研究数据库（NHIRD）来调查SGLT2抑制剂给药与EC发生率之间的潜在关联。针对一项回顾性队列研究，将T2DM参与者分为SGLT2抑制剂使用者和非SGLT2抑制剂使用者。匹配后,共有163,668和327,336名参与者被纳入SGLT2抑制剂组和对照组，分别。根据诊断，主要结果被认为是EC的发展，image,和程序代码。Cox比例风险回归用于生成两组之间EC的校正风险比（aHR）和95％置信区间（CI）。在SGLT2抑制剂组和对照组中观察到422和876例EC事件，分别。与对照组相比，SGLT2抑制剂组的EC形成发生率显着降低（aHR：0.87，95％CI：0.76-0.99）。在亚组分析中，在60岁以下的T2DM个体中,SGLT2抑制剂给药与EC发生率降低存在相关性。此外，SGLT2抑制剂给药与较低EC发生率之间的关联仅在SGLT2抑制剂给药1年以下的T2DM人群中呈现(aHR:0.58,95%CI:0.45~0.73).总之,SGLT2抑制剂的给药与T2DM人群EC发生率降低相关.
